Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

120.04 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,011
Open 120.04
Bid (Size) 119.56 (2)
Ask (Size) 119.65 (1)
Prev. Close 120.04
Today's Range 120.04 - 120.04
52wk Range 92.94 - 148.15
Shares Outstanding N/A
Dividend Yield 1.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 No-Brainer Growth Stocks to Buy in October
These stocks look like slam-dunk picks for growth investors. 
Via The Motley Fool
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga

Performance

YTD
+17.56%
+17.56%
1 Month
-12.38%
-12.38%
3 Month
-15.10%
-15.10%
6 Month
-3.12%
-3.12%
1 Year
+18.68%
+18.68%

More News

Read More
Criminal Networks Cash In On Demand For Weight Loss Drugs, Authorities Say
Via Benzinga
Topics Law Enforcement
Exposures Legal
Analyst Ratings For Novo Nordisk
Via Benzinga
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Via Benzinga
A Closer Look at Novo Nordisk's Options Market Dynamics
Via Benzinga
Novo
Via Talk Markets
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Via Benzinga
Exposures Product Safety
2 No-Brainer Dividend Growth Stocks to Buy Right Now
Via The Motley Fool
Got $5,000? These 3 Growth Stocks Are on Sale Right Now.
Via The Motley Fool
What's Going With WeightWatchers Stock On Wednesday?
Via Benzinga
Exposures Product Safety
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Via MarketBeat
Prediction: 3 of Wall Street's Most Influential Stocks Can Plunge if Kamala Harris Wins in November
Via The Motley Fool
Billion-Dollar News for Eli Lilly Stock Investors
Via The Motley Fool
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
Via Benzinga
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
Via Benzinga
Prediction: These 2 Stocks Will Join Nvidia, Meta, Apple, Amazon, and Microsoft in the Trillion-Dollar Club by 2030
Via The Motley Fool
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Via Benzinga
Exposures Product Safety
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Via Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Via Benzinga
Exposures Product Safety
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
Via Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.